ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies

被引：3
|
作者：
Cha, Seung [1 ]
Charbonneau, Morgan [1 ]
Brito, Alfonso [1 ]
Habibi, Ania [1 ]
Pham, Christina [1 ]
Nguyen, Cokey [1 ]
机构：
[1] Atara Biotherapeut, Thousand Oaks, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181199
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies
    Martyniszyn, Alexandra
    Krahl, Ann-Christin
    Andre, Maya C.
    Hombach, Andreas A.
    Abken, Hinrich
    HUMAN GENE THERAPY, 2017, 28 (12) : 1147 - 1157
  • [2] Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently
    Zhaoqi Chen
    Yan Liu
    Nianci Chen
    Haiyan Xing
    Zheng Tian
    Kejing Tang
    Qing Rao
    Yingxi Xu
    Ying Wang
    Min Wang
    Jianxiang Wang
    Science China(Life Sciences) , 2023, (04) : 754 - 770
  • [3] Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently
    Zhaoqi Chen
    Yan Liu
    Nianci Chen
    Haiyan Xing
    Zheng Tian
    Kejing Tang
    Qing Rao
    Yingxi Xu
    Ying Wang
    Min Wang
    Jianxiang Wang
    Science China(Life Sciences), 2023, 66 (04) : 754 - 770
  • [4] Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently
    Chen, Zhaoqi
    Liu, Yan
    Chen, Nianci
    Xing, Haiyan
    Tian, Zheng
    Tang, Kejing
    Rao, Qing
    Xu, Yingxi
    Wang, Ying
    Wang, Min
    Wang, Jianxiang
    SCIENCE CHINA-LIFE SCIENCES, 2023, 66 (04) : 754 - 770
  • [5] Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently
    Zhaoqi Chen
    Yan Liu
    Nianci Chen
    Haiyan Xing
    Zheng Tian
    Kejing Tang
    Qing Rao
    Yingxi Xu
    Ying Wang
    Min Wang
    Jianxiang Wang
    Science China Life Sciences, 2023, 66 : 754 - 770
  • [6] ALLOGENEIC CD19 CAR EBV T CELLS FOR THE TREATMENT OF B-CELL DRIVEN AUTOIMMUNE DISEASES
    Brito, A.
    Habibi, A.
    Cha, S.
    Charbonneau, M.
    Foubert, P.
    Pham, C. D.
    Nguyen, C.
    CYTOTHERAPY, 2024, 26 (06) : E23 - E23
  • [7] Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies
    Zurko, Joanna C.
    Xu, Huiqing
    Chaney, Katherine
    Schneider, Dina
    Szabo, Aniko
    Hari, Parameswaran
    Johnson, Bryon D.
    Shah, Nirav N.
    CYTOTHERAPY, 2022, 24 (08) : 767 - 773
  • [8] CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas.
    Ghafouri, Sanaz Noelle
    Walthers, Christopher
    Roshandell, Mobina
    Ji, Brenda
    Trent, Jacqueline
    Chen, Jia Ming
    Naparstek, Jacob
    Harris, Caitlin
    Schweppe, Thomas
    Nawaly, Karla K.
    Mead, Monica
    de Vos, Sven
    Young, Patricia
    Oliai, Caspian
    Schiller, Gary
    Timmerman, John M.
    Chen, Yvonne Y.
    Larson, Sarah
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Combating antigen escape with CD19/CD20 bispecific CAR-T cell therapy
    Zah, Eugenia
    Lin, Meng-Yin
    Jensen, Michael C.
    Silva-Benedict, Anne
    Chen, Yvonne Y.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [10] Preclinical development of API-192: An engineered CAR-NKT allogeneic cell therapy targeting CD19 and CD20 for the treatment of B-cell malignancies
    Gov, Lanny
    Yu, Jiaji J.
    Qubain, Maha
    Pompura, Saige L.
    Allen, Sean D.
    Christopher, Michael A.
    Wiezorek, Jeff
    CANCER RESEARCH, 2024, 84 (07)
12345